SCHEMBL13290977

SCHEMBL13290977

CN(C)CCN(C)C(=O)[C@H]1CC[C@H](C(=O)Nc2c(C(=O)Nc3ccc(Cl)cn3)oc3ccncc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HSD17B10 Q99714 3/20 0.40
▸ KMT2A Q03164 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ F10 P00742 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ DEGS1 O15121 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ TP53 P04637 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ DHODH Q02127 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ GSK3A P49840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13291009 0.91 KMT2A (0.44) SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1
SCHEMBL13664995 0.91 SMN1; SMN2 (0.54) SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1
SCHEMBL13290972 0.90 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10KMT2AMEN1F10
SCHEMBL13290510 0.87 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10KMT2AMEN1F10
SCHEMBL13290737 0.87 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10KMT2AMEN1F10
SCHEMBL13290980 0.85 SMN1; SMN2 (0.39) SMN1; SMN2HSD17B10KMT2AMEN1F10
SCHEMBL13290506 0.85 SMN1; SMN2 (0.46) SMN1; SMN2HSD17B10KMT2AMEN1F10
SCHEMBL13664998 0.84 SMN1; SMN2 (0.54) SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1
SCHEMBL13291017 0.84 F10 (0.47) SMN1; SMN2HSD17B10KMT2AMEN1F10
SCHEMBL13291010 0.84 MAPT (0.54) SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885HSD17B10 943/4885KMT2A 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback